In col10a1:nlGFP/rankl:HSE:CFP medaka, both POG and RES suppressed Rankl-stimulated osteoclastogenesis and bone loss by reducing Rankl expression, suggesting that these compounds may not only reduce bone loss but also increase bone mass, and therefore may be useful for the management of metabolic bone disorders, including osteoporosis [11,12]. The gene discussed is TNFSF11; the disease is metabolic bone disorder.